JAZZ LongStrong financials and earnings growth appears to have bottomed out and is now on the trend up. Healthcare can also be a hedge against inflation, which has a serious chance of reemerging, especially if rates were to pause.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.69 EUR
375.84 M EUR
3.47 B EUR
58.39 M
About Jazz Pharmaceuticals plc
Sector
CEO
Bruce C. Cozadd
Headquarters
Dublin
Website
Founded
2005
ISIN
IE00B4Q5ZN47
FIGI
BBG000Q80574
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
J
JAZZ5172103
Jazz Securities Designated Activity Company 4.375% 15-JAN-2029Yield to maturity
5.94%
Maturity date
Jan 15, 2029
Explore more bonds
Frequently Asked Questions
The current price of J7Z is 116.10 EUR — it has decreased by −1.69% in the past 24 hours. Watch JAZZ PHARMACEUTICALS PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange JAZZ PHARMACEUTICALS PLC stocks are traded under the ticker J7Z.
J7Z stock has risen by 5.79% compared to the previous week, the month change is a 7.50% rise, over the last year JAZZ PHARMACEUTICALS PLC has showed a 0.83% increase.
We've gathered analysts' opinions on JAZZ PHARMACEUTICALS PLC future price: according to them, J7Z price has a max estimate of 214.59 EUR and a min estimate of 112.89 EUR. Watch J7Z chart and read a more detailed JAZZ PHARMACEUTICALS PLC stock forecast: see what analysts think of JAZZ PHARMACEUTICALS PLC and suggest that you do with its stocks.
J7Z stock is 2.79% volatile and has beta coefficient of 0.64. Track JAZZ PHARMACEUTICALS PLC stock price on the chart and check out the list of the most volatile stocks — is JAZZ PHARMACEUTICALS PLC there?
Today JAZZ PHARMACEUTICALS PLC has the market capitalization of 6.98 B, it has increased by 15.65% over the last week.
Yes, you can track JAZZ PHARMACEUTICALS PLC financials in yearly and quarterly reports right on TradingView.
JAZZ PHARMACEUTICALS PLC is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
J7Z earnings for the last quarter are 5.94 EUR per share, whereas the estimation was 4.94 EUR resulting in a 20.22% surprise. The estimated earnings for the next quarter are 5.62 EUR per share. See more details about JAZZ PHARMACEUTICALS PLC earnings.
JAZZ PHARMACEUTICALS PLC revenue for the last quarter amounts to 947.51 M EUR, despite the estimated figure of 930.97 M EUR. In the next quarter, revenue is expected to reach 1.01 B EUR.
J7Z net income for the last quarter is 193.15 M EUR, while the quarter before that showed 157.38 M EUR of net income which accounts for 22.73% change. Track more JAZZ PHARMACEUTICALS PLC financial stats to get the full picture.
No, J7Z doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 2.80 K employees. See our rating of the largest employees — is JAZZ PHARMACEUTICALS PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JAZZ PHARMACEUTICALS PLC EBITDA is 1.25 B EUR, and current EBITDA margin is 33.85%. See more stats in JAZZ PHARMACEUTICALS PLC financial statements.
Like other stocks, J7Z shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JAZZ PHARMACEUTICALS PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JAZZ PHARMACEUTICALS PLC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JAZZ PHARMACEUTICALS PLC stock shows the buy signal. See more of JAZZ PHARMACEUTICALS PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.